EE05394B1 - Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis - Google Patents

Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis

Info

Publication number
EE05394B1
EE05394B1 EEP200500033A EEP200500033A EE05394B1 EE 05394 B1 EE05394 B1 EE 05394B1 EE P200500033 A EEP200500033 A EE P200500033A EE P200500033 A EEP200500033 A EE P200500033A EE 05394 B1 EE05394 B1 EE 05394B1
Authority
EE
Estonia
Prior art keywords
treatment
quinoline compounds
latent tuberculosis
tuberculosis
latent
Prior art date
Application number
EEP200500033A
Other languages
English (en)
Estonian (et)
Inventor
Jozef Lodewijk Marcel Andries Koenraad
Koul Anil
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35717702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05394(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE200500033A publication Critical patent/EE200500033A/xx
Publication of EE05394B1 publication Critical patent/EE05394B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200500033A 2004-12-24 2005-12-05 Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis EE05394B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04078529 2004-12-24
EP05105008 2005-06-08

Publications (2)

Publication Number Publication Date
EE200500033A EE200500033A (et) 2006-08-15
EE05394B1 true EE05394B1 (et) 2011-04-15

Family

ID=35717702

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200500033A EE05394B1 (et) 2004-12-24 2005-12-05 Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis

Country Status (30)

Country Link
US (1) US20060142279A1 (pl)
EP (1) EP1830850B1 (pl)
CN (1) CN103142595B (pl)
AP (1) AP2327A (pl)
AR (1) AR051790A1 (pl)
AT (1) ATE501721T1 (pl)
AU (1) AU2005242138B2 (pl)
BR (1) BRPI0506400B8 (pl)
CA (1) CA2529265C (pl)
CR (1) CR9267A (pl)
CY (1) CY1112247T1 (pl)
DE (1) DE602005026984D1 (pl)
DK (1) DK1830850T3 (pl)
EE (1) EE05394B1 (pl)
HR (1) HRP20110392T1 (pl)
IL (1) IL184123A (pl)
LV (1) LV13469B (pl)
ME (1) ME01207B (pl)
MY (1) MY145845A (pl)
NI (1) NI200700146A (pl)
NO (1) NO340376B1 (pl)
NZ (1) NZ555460A (pl)
PA (1) PA8654801A1 (pl)
PL (1) PL1830850T3 (pl)
PT (1) PT1830850E (pl)
RS (1) RS51730B (pl)
SI (1) SI1830850T1 (pl)
TR (1) TR200504892A1 (pl)
TW (1) TWI404535B (pl)
WO (1) WO2006067048A1 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1527050E (pt) * 2002-07-25 2010-06-22 Janssen Pharmaceutica Nv Derivados de quinolina e sua utilização como inibidores de micobactérias
CA2612614C (en) * 2005-06-28 2017-07-25 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO2752B1 (en) * 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
CA2711912A1 (en) * 2008-01-14 2009-07-23 Jyoti Chattopadhyaya Quinoline, naphthalene and conformationally constrained quinoline or naphthalene derivates as anti-mycobacterial agents
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
US8741917B2 (en) 2009-01-15 2014-06-03 Rutgers, The State University Of New Jersey Benzo [C] phenanthridines as antimicrobial agents
US20120059026A1 (en) 2009-04-30 2012-03-08 University Of Medicine And Dentistry Of New Jersey Antimicrobial agents
WO2011156626A1 (en) 2010-06-09 2011-12-15 Rutgers, The State University Of New Jersey Antimicrobial agents
CA2803890A1 (en) 2010-06-25 2011-12-29 Rutgers, The State University Of New Jersey Antimicrobial agents
WO2013106756A2 (en) 2012-01-13 2013-07-18 Rutgers, The State University Of New Jersey Antimicrobial agents
AU2013235038A1 (en) 2012-03-21 2014-10-09 Malvika Kaul Antimicrobial agents
KR102110366B1 (ko) 2012-04-27 2020-05-14 얀센 파마슈티카 엔.브이. 항균성 퀴놀린 유도체
US9133167B2 (en) 2012-04-27 2015-09-15 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
US9458150B2 (en) 2013-11-08 2016-10-04 Rutgers, The State University Of New Jersey Antimicrobial agents
CN114129526A (zh) 2015-01-27 2022-03-04 詹森药业有限公司 可分散组合物
CN109195957A (zh) 2016-02-25 2019-01-11 塔克西斯医药股份有限公司 合成方法和中间体
EA201891644A1 (ru) * 2016-03-07 2019-04-30 Зе Глобал Эллайенс Фо Тб Драг Девелопмент, Инк. Антибактериальные соединения и их применение
RU2629369C1 (ru) * 2016-10-05 2017-08-29 Федеральное Государственное Унитарное Предприятие "Государственный Ордена Трудового Красного Знамени Научно-Исследовательский Институт Химических Реактивов И Особо Чистых Химических Веществ" Четвертичные аммонийные производные 2-аминотиофен-3-карбоксилатов, обладающие противотуберкулезной активностью
CA3058183A1 (en) 2017-03-30 2018-10-04 Taxis Pharmaceuticals, Inc. Synthetic processes and synthetic intermediates towardthe production of txa709
WO2019012100A1 (en) 2017-07-14 2019-01-17 Janssen Pharmaceutica Nv EXTENDED ACTION FORMULATIONS
RU2661151C1 (ru) * 2017-12-14 2018-07-12 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Селективные ингибиторы глицеральдегид-3-фосфатдегидрогеназы микобактерий
KR20210113628A (ko) 2019-01-09 2021-09-16 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서의 조합물
WO2022008643A1 (en) 2020-07-09 2022-01-13 Janssen Pharmaceutica Nv Long-acting formulations
EP4178541A1 (en) 2020-07-09 2023-05-17 JANSSEN Pharmaceutica NV Long-acting formulations
KR20230107275A (ko) 2020-11-12 2023-07-14 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
CN119968203A (zh) 2022-09-28 2025-05-09 詹森药业有限公司 长效配制品
CN121941498A (zh) 2023-09-28 2026-04-28 詹森药业有限公司 用于治疗非结核分枝杆菌的atp合酶抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038536A1 (es) * 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
PT1527050E (pt) * 2002-07-25 2010-06-22 Janssen Pharmaceutica Nv Derivados de quinolina e sua utilização como inibidores de micobactérias

Also Published As

Publication number Publication date
ME01207B (me) 2013-03-20
MY145845A (en) 2012-04-30
CA2529265C (en) 2014-02-11
US20060142279A1 (en) 2006-06-29
CR9267A (es) 2008-09-09
EP1830850B1 (en) 2011-03-16
HK1186125A1 (en) 2014-03-07
AP2327A (en) 2011-11-25
NZ555460A (en) 2008-11-28
EE200500033A (et) 2006-08-15
PT1830850E (pt) 2011-05-31
NO340376B1 (no) 2017-04-10
IL184123A0 (en) 2008-12-29
TR200504892A1 (tr) 2010-04-21
TW200637551A (en) 2006-11-01
RS51730B (sr) 2011-10-31
NO20073823L (no) 2007-07-23
CY1112247T1 (el) 2015-12-09
SI1830850T1 (sl) 2011-07-29
AU2005242138B2 (en) 2011-05-26
NI200700146A (es) 2019-05-10
BRPI0506400B1 (pt) 2021-04-06
CN103142595B (zh) 2015-05-06
EP1830850A1 (en) 2007-09-12
WO2006067048A1 (en) 2006-06-29
PL1830850T3 (pl) 2011-07-29
IL184123A (en) 2011-10-31
CA2529265A1 (en) 2006-06-24
BRPI0506400A8 (pt) 2017-09-12
ATE501721T1 (de) 2011-04-15
BRPI0506400A (pt) 2006-08-29
HRP20110392T1 (hr) 2011-06-30
TWI404535B (zh) 2013-08-11
AP2007004054A0 (en) 2007-06-30
CN103142595A (zh) 2013-06-12
DK1830850T3 (da) 2011-06-14
AU2005242138A1 (en) 2006-07-13
AR051790A1 (es) 2007-02-07
LV13469B (en) 2007-01-20
PA8654801A1 (es) 2006-08-03
BRPI0506400B8 (pt) 2021-05-25
DE602005026984D1 (de) 2011-04-28

Similar Documents

Publication Publication Date Title
IL184123A0 (en) Quinoline derivatives for the treatment of latent tuberculosis
CY2017013I1 (el) ΑΝΤΙΣΩΜΑ ΕΝΑΝΤΙΟΝ PDGFR-α ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΟΓΚΩΝ
SI3424932T1 (sl) Boronoftalidi za terapevtsko uporabo
IL181524A0 (en) Heterocyclic compounds and methods of use
DK1720554T3 (da) Anvendelse af meloxicam til behandling af luftvejssygdomme hos svin
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
DE602005015215D1 (de) Orthosubstituierte aryl- oder heteroarylamidverbindungen
NO20070251A (no) Brønnbehandling
NO20070297A (no) Brønnbehandling
DE602005018315D1 (de) Rollstuhl
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
IL181819A (en) Use of benzo-fused compounds for the preparation of a medicament and methods making use of said compounds
HRP20150320T1 (xx) Formulacije i metode za lijeäśenje amiloidoze
PT1763520E (pt) Utilização de benzopiranonas trissubstituídas
ZA200705160B (en) Quinoline derivatives for the treatment of latent tuberculosis
FI20040180L (fi) Koostumus psoriasis-taudin hoitamiseksi
EP1759020A4 (en) ACACS AS MODIFIERS OF THE IGF PATHWAY AND METHODS OF USE
DK2301576T3 (da) Terapeutisk anvendelse af anti-CS1-antistoffer
SE0403119D0 (sv) Therapeutic agents
SE0400718D0 (sv) Therapeutic agents
SE0400613D0 (sv) New compounds and use thereof
SE0402780D0 (sv) Therapeutic agents
HUE036189T2 (hu) Monofenol, benzoldiol vagy szulfhidril vegyületek melanómák kezelésében való alkalmazásra
EE200400064A (et) Ambroksooli kasutamine neelupõletiku ravimiseks

Legal Events

Date Code Title Description
HC1A Change of owner name